G-401细胞

G-401/G-401细胞系/G-401细胞株/G-401人肾癌Wilms细胞

Cell line name G-401

Synonyms G401; G 401

Accession CVCL_0270

Resource Identification Initiative To cite this cell line use: G-401 (RRID:CVCL_0270)

Comments Problematic cell line: Misclassified. Originally thought to be a Wilms tumor cell line but is a kidney rhabdoid tumor cell line (PubMed=8382007; PubMed=30924592).

Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Part of: COSMIC cell lines project.

Population: Caucasian.

Microsatellite instability: Stable (MSS) (Sanger).

Omics: Deep exome analysis.

Omics: Deep quantitative proteome analysis.

Omics: DNA methylation analysis.

Omics: H3K27ac ChIP-seq epigenome analysis.

Omics: H3K27me3 ChIP-seq epigenome analysis.

Omics: H3K4me3 ChIP-seq epigenome analysis.

Omics: SNP array analysis.

Omics: Transcriptome analysis by microarray.

Omics: Transcriptome analysis by RNAseq.

Derived from site: In situ; Kidney; UBERON=UBERON_0002113.

PubMed=8382007; PMCID=PMC1886739

Garvin A.J., Re G.G., Tarnowski B.I., Hazen-Martin D.J., Sens D.A.

The G401 cell line, utilized for studies of chromosomal changes in Wilms' tumor, is derived from a rhabdoid tumor of the kidney.

Am. J. Pathol. 142:375-380(1993)

 

PubMed=9671307; DOI=10.1038/28212

Versteege I., Sevenet N., Lange J., Rousseau-Merck M.-F., Ambros P.F., Handgretinger R., Aurias A., Delattre O.

Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer.

Nature 394:203-206(1998)

 

PubMed=10397258

Rousseau-Merck M.-F., Versteege I., Legrand I., Couturier J., Mairal A., Delattre O., Aurias A.

hSNF5/INI1 inactivation is mainly associated with homozygous deletions and mitotic recombinations in rhabdoid tumors.

Cancer Res. 59:3152-3156(1999)

 

PubMed=10602515; DOI=10.1038/sj.onc.1203168

DeCristofaro M.F., Betz B.L., Wang W.-D., Weissman B.E.

Alteration of hSNF5/INI1/BAF47 detected in rhabdoid cell lines and primary rhabdomyosarcomas but not Wilms' tumors.

Oncogene 18:7559-7565(1999)

 

PubMed=20164919; DOI=10.1038/nature08768; PMCID=PMC3145113

Bignell G.R., Greenman C.D., Davies H.R., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Signatures of mutation and selection in the cancer genome.

Nature 463:893-898(2010)

 

PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458; PMCID=PMC2881662

Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Cancer Res. 70:2158-2164(2010)

 

PubMed=22460905; DOI=10.1038/nature11003; PMCID=PMC3320027

Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Nature 483:603-607(2012)

 

PubMed=25877200; DOI=10.1038/nature14397

Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M., Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S., Neve R.M.

A resource for cell line authentication, annotation and quality control.

Nature 520:307-311(2015)

 

PubMed=26351324; DOI=10.1158/1535-7163.MCT-15-0074; PMCID=PMC4636476

Teicher B.A., Polley E.C., Kunkel M., Evans D., Silvers T.E., Delosh R.M., Laudeman J., Ogle C., Reinhart R., Selby M., Connelly J., Harris E., Monks A., Morris J.

Sarcoma cell line screen of oncology drugs and investigational agents identifies patterns associated with gene and microRNA expression.

Mol. Cancer Ther. 14:2452-2462(2015)

 

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017; PMCID=PMC4967469

Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Mo T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

A landscape of pharmacogenomic interactions in cancer.

Cell 166:740-754(2016)